以岭药业：盐酸美金刚化学原料药上市申请获批

Core Viewpoint - Yiling Pharmaceutical (002603) announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of Memantine Hydrochloride, a chemical raw material drug [1] Group 1 - The approved drug, Memantine Hydrochloride, is a voltage-dependent, moderate-affinity non-competitive NMDA receptor antagonist [1] - Memantine Hydrochloride is used to block pathological increases in glutamate concentration that lead to neuronal damage, specifically for the treatment of moderate to severe Alzheimer's disease [1]